Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276188 | 0.83 | LMNA (0.39) | OPRM1LMNADNM1NAAAFDPS | |
| SCHEMBL276813 | 0.81 | — | — | |
| SCHEMBL10685835 | 0.80 | OPRM1 (0.39) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL1960012 | 0.77 | TSHR (0.43) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL2601778 | 0.75 | TSHR (0.42) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL387047 | 0.75 | OPRM1 (0.39) | OPRM1LMNADNM1FDPSTSHR | |
| Hydrochloric Acid SCHEMBL5480968 | 0.75 | TSHR (0.42) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL277510 | 0.75 | MAPT (0.40) | OPRM1LMNADNM1FDPSTSHR | |
| Hydrochloric Acid SCHEMBL29189739 | 0.75 | TSHR (0.42) | OPRM1LMNADNM1FDPSTSHR | |
| SCHEMBL12939814 | 0.75 | TSHR (0.42) | OPRM1LMNADNM1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | OPRM1 616/4885LMNA 1745/4885DNM1 4670/4885 |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | OPRM1 1047/4885LMNA 257/4885DNM1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.